Latest News

Results from a US Real-World Evidence (RWE) study conducted by PEGUS were recently published in Contraception, an international reproductive health journal and the official journal…

The Sterling Institutional Review Board (IRB) featured PEGUS Research’s innovative and versatile marketing strategies in their latest Whitepaper article titled “PPC and Social Media Patient…

On 16 August, 2021, the UK Medicine and Healthcare products Regulatory Agency (MHRA) made Nuromol, a medicine that contains 200mg of ibuprofen and 500mg of…

On 17 June 2021, the US Food and Drug Administration (FDA) announced approval of a new nasal antihistamine (Astepro Allergy and Children’s Astepro Allergy) for…

Clark Richardson, PEGUS President & CEO, participated in a 09 June 2021 FDA public workshop titled, “The Nonprescription Drug Facts Label in a Changing Consumer…

Innovating at Unprecedented Pace COVID-19 prompted dramatic changes in the way we conduct research.  In the months since the pandemic began, we have completed literally…

We are pleased to announce Brandon Henrie has been promoted to Vice President – Finance and Strategy.  In this new role, Brandon focuses on company…

On 28 Feb. 2020, the US Food and Drug Administration (FDA) approved a novel fixed-dose combination oral pain reliever (Advil Dual Action with Acetaminophen) for…